Eastern Cooperative Oncology Group (ECOG) investigators have tested a variety of single-agent and combination regimens in @entity1 with @entity1149 ( @entity1149 ) during the last 2 decades. The following observations have been made. (1) The @entity1138 / @entity5713 / @entity900 regimen produced a trend for higher response rates in two studies and a significantly higher response rate in a third study. Survival, however, tended to be shorter in @entity1 receiving this regimen. (2) @entity3003 produced a 9% overall response rate and a median survival of 31.7 weeks, which was slightly but significantly longer than the median survivals obtained with three combination chemotherapy regimens. (3) @entity1311 produced an overall response rate of 21% and a 1-year survival rate of 40% in previously untreated @entity1149 @entity1 . This observation led to a phase III trial in which @entity1311 (135 mg/m2 and 250 mg/m2) was combined with @entity900 and compared with @entity2879 / @entity900 . Response rates for each of the @entity1311 / @entity900 regimens (26% for 135 mg/m2 @entity1311 and 31% for 250 mg/m2) were significantly higher than the response rate for @entity2879 / @entity900 (12%), but response between the two @entity1311 / @entity900 arms was not significantly different. At this point, there is a trend toward longer survival in each of the @entity1311 / @entity900 arms, but the final survival analyses have not been completed. In the next phase III trial, ECOG will evaluate @entity1311 (135 mg/m2) plus @entity900 in comparison to three other regimens-- @entity1205 / @entity900 , @entity136 / @entity900 , and @entity3003 / @entity1311 .

Eastern Cooperative Oncology Group experience with chemotherapy in advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin'] @entity1138 :: ('MESH:D016685', 'Chemical') :: ['mitomycin'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel', 'Paclitaxel'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity5713 :: ('MESH:D014747', 'Chemical') :: ['vinblastine']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
